A Canadian pharmaceutical company is partnering with Harvard University and Brigham and Women’s Hospital to develop an oral drug that blocks the Ebola virus and could be tested on humans as early as this year. James Cunningham, associate professor of medicine at Brigham and Women’s, is the lead researcher on the project.
